Monte Rosa Therapeutics Ownership | Who Owns Monte Rosa Therapeutics?

Monte Rosa Therapeutics Ownership Summary

Monte Rosa Therapeutics is owned by 60.69% institutional investors, 0.71% insiders, and 38.60% retail investors. Nea management company is the largest institutional shareholder, holding 12.79% of GLUE shares. T. Rowe Price New Horizons is the top mutual fund, with 5.55% of its assets in Monte Rosa Therapeutics shares.

GLUE Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Monte Rosa Therapeutics	60.69%	0.71%	38.60%
Sector	Healthcare Stocks	49.73%	8.84%	41.43%
Industry	Biotech Stocks	47.04%	8.74%	44.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Nea management company	7.69M	12.79%	$28.77M
Price t rowe associates inc /md/	5.98M	9.94%	$22.36M
Fmr	5.09M	8.47%	$19.06M
Baker bros. advisors lp	4.92M	8.17%	$18.39M
Avoro capital advisors	4.54M	7.54%	$16.96M
Suvretta capital management	2.66M	4.42%	$9.94M
Vanguard group	2.55M	4.23%	$9.53M
Blackrock	2.36M	3.92%	$8.83M
Aisling capital management lp	1.47M	2.45%	$5.51M
Alphabet	1.46M	2.43%	$5.48M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Aisling capital management lp	1.47M	2.38%	$5.51M
Nea management company	7.69M	2.16%	$28.77M
Suvretta capital management	2.66M	0.37%	$9.94M
Alphabet	1.46M	0.28%	$5.48M
Vestal point capital, lp	890.00K	0.25%	$3.33M
Baker bros. advisors lp	4.92M	0.23%	$18.39M
Avoro capital advisors	4.54M	0.23%	$16.96M
Sphera funds management	375.00K	0.19%	$1.40M
Long corridor asset management	40.00K	0.14%	$149.60K
Casdin capital	261.01K	0.07%	$976.19K

Top Buyers

Holder	Shares	% Assets	Change
Suvretta capital management	2.66M	0.37%	2.66M
Vanguard group	2.55M	0.00%	911.25K
Vestal point capital, lp	890.00K	0.25%	890.00K
Price t rowe associates inc /md/	5.98M	0.00%	880.80K
Sphera funds management	375.00K	0.19%	375.00K

Top Sellers

Holder	Shares	% Assets	Change
Casdin capital	261.01K	0.07%	-249.87K
Fmr	5.09M	0.00%	-245.83K
Millennium management	20.93K	-	-129.10K
Sarasin & partners llp	-	-	-65.08K
Gsa capital partners llp	-	-	-25.35K

New Positions

Holder	Shares	% Assets	Change	Value
Suvretta capital management	2.66M	0.37%	2.66M	$9.94M
Vestal point capital, lp	890.00K	0.25%	890.00K	$3.33M
D. e. shaw	23.42K	0.00%	23.42K	$87.60K
Castleview partners	18.95K	0.04%	18.95K	$70.87K
Corebridge financial	16.39K	0.00%	16.39K	$61.31K

Sold Out

Holder	Change
Nelson, van denburg & campbell wealth management group	-6.00
Metropolitan life insurance co/ny	-1.82K
Metlife investment management	-11.42K
Mirae asset global investments	-11.95K
Pdt partners	-13.96K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2024	84	9.09%	49,773,785	8.59%	60	1.47%	54	14.89%	12	-
Jun 30, 2024	76	7.04%	45,836,354	14.90%	76	1.26%	47	62.07%	12	-47.83%
Mar 31, 2024	71	-10.13%	39,892,663	-0.52%	77	1.20%	29	3.57%	23	-11.54%
Dec 31, 2023	79	5.33%	40,102,427	-4.61%	80	1.11%	28	-30.00%	26	52.94%
Sep 30, 2023	75	7.14%	42,042,262	5.78%	85	1.31%	40	-4.76%	17	54.55%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
T. Rowe Price New Horizons	3.41M	5.55%	-10.73K
US Small-Cap Growth II Equity Comp	3.41M	5.55%	-12.11K
HBM Healthcare Investments AG Ord	1.41M	2.29%	-
Vanguard Total Stock Mkt Idx Inv	1.35M	2.20%	-
iShares Russell 2000 ETF	1.03M	1.67%	-2.31K
Fidelity Advisor Biotechnology I	982.76K	1.60%	-
Fidelity Growth Compy Commingled Pl S	976.03K	1.59%	5.21K
Fidelity Growth Compy Commingled Pl O	970.82K	1.58%	-
T. Rowe Price Health Sciences	923.02K	1.50%	115.59K
Fidelity Select Pharmaceuticals Port	796.40K	1.30%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Oct 28, 2024	Versant Venture Capital VI, L.P.	-	Sell	$869.24K
Oct 29, 2024	Versant Venture Capital VI, L.P.	-	Sell	$146.79K
Oct 29, 2024	Versant Venture Capital VI, L.P.	-	Sell	$475.01K
Sep 20, 2024	Versant Venture Capital VI, L.P.	-	Sell	$7.40M
Sep 12, 2024	Versant Venture Capital VI, L.P.	-	Sell	$96.31K

Insider Transactions Trends

Date	Buy	Sell
2024 Q4	-	3
2024 Q3	-	5
2024 Q2	-	1
2024 Q1	-	-
2023 Q3	-	-

GLUE Ownership FAQ

Who Owns Monte Rosa Therapeutics?

Monte Rosa Therapeutics shareholders are primarily institutional investors at 60.69%, followed by 0.71% insiders and 38.60% retail investors. The average institutional ownership in Monte Rosa Therapeutics's industry, Biotech Stocks , is 47.04%, which Monte Rosa Therapeutics exceeds.

Who owns the most shares of Monte Rosa Therapeutics?

Monte Rosa Therapeutics’s largest shareholders are Nea management company (7.69M shares, 12.79%), Price t rowe associates inc /md/ (5.98M shares, 9.94%), and Fmr (5.09M shares, 8.47%). Together, they hold 31.19% of Monte Rosa Therapeutics’s total shares outstanding.

Does Blackrock own Monte Rosa Therapeutics?

Yes, BlackRock owns 3.92% of Monte Rosa Therapeutics, totaling 2.36M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 8.83M$. In the last quarter, BlackRock increased its holdings by 53.08K shares, a 2.30% change.

Who is Monte Rosa Therapeutics’s biggest shareholder by percentage of total assets invested?

Aisling capital management lp is Monte Rosa Therapeutics’s biggest shareholder by percentage of total assets invested, with 2.38% of its assets in 1.47M Monte Rosa Therapeutics shares, valued at 5.51M$.

Who is the top mutual fund holder of Monte Rosa Therapeutics shares?

T. Rowe Price New Horizons is the top mutual fund holder of Monte Rosa Therapeutics shares, with 5.55% of its total shares outstanding invested in 3.41M Monte Rosa Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools